EE9900010A - T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks - Google Patents

T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks

Info

Publication number
EE9900010A
EE9900010A EEP199900010A EE9900010A EE9900010A EE 9900010 A EE9900010 A EE 9900010A EE P199900010 A EEP199900010 A EE P199900010A EE 9900010 A EE9900010 A EE 9900010A EE 9900010 A EE9900010 A EE 9900010A
Authority
EE
Estonia
Prior art keywords
cd40l
bam
treatment
technology
smooth muscle
Prior art date
Application number
EEP199900010A
Other languages
English (en)
Estonian (et)
Inventor
J. Yellin Michael
Chess Leonard
N. Karpusas Mihail
W. Thomas David
Original Assignee
The Trustees Of Columbia University In The City Of New York
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York, Biogen, Incorporated filed Critical The Trustees Of Columbia University In The City Of New York
Publication of EE9900010A publication Critical patent/EE9900010A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
EEP199900010A 1996-07-08 1997-07-03 T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks EE9900010A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67773096A 1996-07-08 1996-07-08
PCT/US1997/012925 WO1998001145A1 (en) 1996-07-08 1997-07-03 Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells

Publications (1)

Publication Number Publication Date
EE9900010A true EE9900010A (et) 1999-06-15

Family

ID=24719894

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900010A EE9900010A (et) 1996-07-08 1997-07-03 T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks

Country Status (20)

Country Link
US (2) US20030219437A1 (ru)
EP (1) EP0956030A4 (ru)
JP (1) JP2000515507A (ru)
CN (1) CN1242809C (ru)
AU (1) AU731299B2 (ru)
BG (1) BG63489B1 (ru)
BR (1) BR9710264A (ru)
CA (1) CA2259962C (ru)
CZ (1) CZ297300B6 (ru)
EA (1) EA004401B1 (ru)
EE (1) EE9900010A (ru)
HU (1) HUP9904669A3 (ru)
IL (1) IL127884A0 (ru)
IS (1) IS4935A (ru)
NO (1) NO990019L (ru)
NZ (1) NZ333602A (ru)
PL (1) PL188408B1 (ru)
SK (1) SK499A3 (ru)
TR (1) TR199900029T2 (ru)
WO (1) WO1998001145A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
US20020173053A1 (en) * 2001-04-27 2002-11-21 Bassam Damaj Multiple simultaneous antigen detection by immunohistochemistry
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
UY32802A (es) * 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
CA3022636A1 (en) * 2016-05-13 2017-11-16 Medimmune, Llc Cd40l-fc fusion polypeptides and methods of use thereof
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6822070B2 (en) * 1996-03-11 2004-11-23 David Baltimore Truncated CRAF1 inhibits CD40 signaling

Also Published As

Publication number Publication date
US20030219437A1 (en) 2003-11-27
BG103148A (en) 1999-10-29
EA004401B1 (ru) 2004-04-29
AU4229297A (en) 1998-02-02
JP2000515507A (ja) 2000-11-21
EP0956030A4 (en) 2001-11-28
AU731299B2 (en) 2001-03-29
CA2259962C (en) 2002-01-22
IS4935A (is) 1998-12-23
NO990019L (no) 1999-03-08
US20080050369A1 (en) 2008-02-28
CZ297300B6 (cs) 2006-11-15
CN1242809C (zh) 2006-02-22
NZ333602A (en) 2000-06-23
BR9710264A (pt) 1999-08-10
HUP9904669A3 (en) 2001-06-28
CN1227494A (zh) 1999-09-01
WO1998001145A1 (en) 1998-01-15
CZ2699A3 (cs) 1999-05-12
IL127884A0 (en) 1999-10-28
HUP9904669A2 (hu) 2000-05-28
EP0956030A1 (en) 1999-11-17
TR199900029T2 (xx) 1999-04-21
NO990019D0 (no) 1999-01-04
SK499A3 (en) 1999-08-06
EA199900091A1 (ru) 1999-08-26
PL331104A1 (en) 1999-06-21
BG63489B1 (bg) 2002-03-29
CA2259962A1 (en) 1998-01-15
PL188408B1 (pl) 2005-01-31

Similar Documents

Publication Publication Date Title
EE9700267A (et) a1L- agonistide kasutamine uriiniinkontinentsuse raviks
NO990851D0 (no) Forbedret apparat for ultralyd-terapeutisk behandling
HK1009939A1 (en) Medicament for treating cardiac inflammatory diseases
FI973002A0 (fi) Terapeuttinen yhdiste - rasvahappokonjugaatit
EE9800158A (et) Epinastiin kasutamiseks valude ravis
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
ID25921A (id) Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
NZ501069A (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
EE200000164A (et) Inimkeha tasakaalu taastamise aparaat
LV11615A (lv) Amidi ar arstnieciskam ipasibam
DE69634572D1 (de) Perfusionssytem zur hyperthermiebehandlung
NO985066D0 (no) Terapeutisk behandling for VEGF-relaterte sykdommer
ID26861A (id) Terapi gabungan untuk pengobatan depresi refaktori
DK64592D0 (da) Peptider til terapeutisk behandling
ID18679A (id) Penggunaan terapi lanjutan
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
EP1039883A4 (en) METHOD FOR TREATING APOLIPOPROTEIN E CONDITIONAL DISEASES
DK0693912T3 (da) Apparat til medicinsk behandling
AU9337598A (en) Magnetically therapeutic treatment device
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
DE69636790D1 (de) Interferon-beta gegen knochenerkrankungen
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
FI943989A0 (fi) Terapeuttisia tai ehkäiseviä aineita peroksilipidiin liittyviin sairauksiin

Legal Events

Date Code Title Description
HC1A Change of owner name